42 related articles for article (PubMed ID: 1260772)
1. Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies.
Nardelli B; Puccetti P; Romani L; Sava G; Bonmassar E; Fioretti MC
Cancer Immunol Immunother; 1984; 17(3):213-7. PubMed ID: 6566603
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives.
Nardelli B; Contessa AR; Romani L; Sava G; Nisi C; Fioretti MC
Cancer Immunol Immunother; 1984; 16(3):157-61. PubMed ID: 6561067
[TBL] [Abstract][Full Text] [Related]
3. Cinnamaldehyde Enhances Antimelanoma Activity through Covalently Binding ENO1 and Exhibits a Promoting Effect with Dacarbazine.
Zhang W; Gao J; Cheng C; Zhang M; Liu W; Ma X; Lei W; Hao E; Hou X; Hou Y; Bai G
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32013122
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of dacarbazine (DTIC) in pregnancy.
Kantrowitz-Gordon I; Hays K; Kayode O; Kumar AR; Kaplan HG; Reid JM; Safgren SL; Ames MM; Easterling TR; Hebert MF
Cancer Chemother Pharmacol; 2018 Mar; 81(3):455-460. PubMed ID: 29305638
[TBL] [Abstract][Full Text] [Related]
5. Adoptive cell therapy with CD4
Li K; Donaldson B; Young V; Ward V; Jackson C; Baird M; Young S
Clin Transl Immunology; 2017 Oct; 6(10):e160. PubMed ID: 29114389
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
Yang C; Cao H; Liu N; Xu K; Ding M; Mao LJ
Drug Des Devel Ther; 2016; 10():3755-3761. PubMed ID: 27895465
[TBL] [Abstract][Full Text] [Related]
7. Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier.
Almoussalam M; Zhu H
J Vis Exp; 2016 Apr; (110):. PubMed ID: 27168058
[TBL] [Abstract][Full Text] [Related]
8. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
9. Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
Foster BJ; Newell DR; Carmichael J; Harris AL; Gumbrell LA; Jones M; Goodard PM; Calvert AH
Br J Cancer; 1993 Feb; 67(2):362-8. PubMed ID: 8431367
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.
Adkins DR; Irvin R; Kuhn J; Boldt DH; Roodman GD; Salzman D; Freytes C; Von Hoff DD; LeMaistre CF
Invest New Drugs; 1993; 11(2-3):169-79. PubMed ID: 8262729
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of drug sensitivity by human metastatic melanoma colony-forming units.
Meyskens FL; Moon TE; Dana B; Gilmartin E; Casey WJ; Chen HS; Franks DH; Young L; Salmon SE
Br J Cancer; 1981 Dec; 44(6):787-97. PubMed ID: 7326191
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.
Breithaupt H; Dammann A; Aigner K
Cancer Chemother Pharmacol; 1982; 9(2):103-9. PubMed ID: 7172404
[TBL] [Abstract][Full Text] [Related]
13. Establishment, characterization, and response to cytotoxic and radiation treatment of three human melanoma cell lines.
Courdi A; Gioanni J; Lalanne CM; Fischel JL; Schneider M; Ettore F; Lambert JC
In Vitro; 1983 Jun; 19(6):453-61. PubMed ID: 6873970
[TBL] [Abstract][Full Text] [Related]
14. Application of a microsomal drug activation system in a human tumor cloning assay.
Metelmann HR; Von Hoff DD
Invest New Drugs; 1983; 1(1):27-32. PubMed ID: 6678855
[TBL] [Abstract][Full Text] [Related]
15. Intestinal and liver toxicity of antineoplastic drugs.
McDonald GB; Tirumali N
West J Med; 1984 Feb; 140(2):250-9. PubMed ID: 6375139
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic drugs in 1990. A review (Part II).
Black DJ; Livingston RB
Drugs; 1990 May; 39(5):652-73. PubMed ID: 2191847
[No Abstract] [Full Text] [Related]
17. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
Frosch PJ; Czarnetzki BM; Macher E; Grundmann E; Gottschalk I
J Cancer Res Clin Oncol; 1979; 95(3):281-6. PubMed ID: 528568
[TBL] [Abstract][Full Text] [Related]
18. The antitumour agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) inhibits rat liver cAMP phosphodiesterase and amplifies hormone effects in hepatocytes and hepatoma cells.
Larsson PG; Haffner F; Brłnstad GO; Christoffersen T
Br J Cancer; 1979 Nov; 40(5):768-73. PubMed ID: 228692
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action and pharmacology studies with DTIC (NSC-45388).
Loo TL; Housholder GE; Gerulath AH; Saunders PH; Farquhar D
Cancer Treat Rep; 1976 Feb; 60(2):149-52. PubMed ID: 1260772
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
